# WEgovy Real World Assessment of Weight Loss in Korea

> **NCT07280221** · — · ENROLLING_BY_INVITATION · sponsor: **Novo Nordisk A/S** · enrollment: 500 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT07280221
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-11-10
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07280221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07280221, "WEgovy Real World Assessment of Weight Loss in Korea". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07280221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*